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Data from a comparative proteomic analysis of three human breast
epithelial cell lines are presented. M13SV1 cells and their tumorigenic
derivatives M13SV1-R2-2 and M13SV1-R2-N1 were used. Proteomic
data were obtained using 2-dimensional gel electrophoresis and sub-
sequent identiﬁcation of proteins by MALDI-TOF mass spectrometry. In
a second experiment, the three cell lines were treated with different
concentrations of the estrogenic compounds β-estradiol or genistein
and alterations in protein expressionwere monitored by 2-dimensional
gel electrophoresis and MALDI-TOF mass spectrometry. Presented data
provide a comprehensive overview of proteomic differences between
the three cell lines and their response to estrogenic stimulation.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biologyore speciﬁc sub-
ject areaCell biology / Toxicology / Proteomicsvier Inc. This is an open access article under the CC BY license
A. Braeuning).
T
H
D
E
E
D
A. Braeuning et al. / Data in Brief 8 (2016) 329–333330ype of data Figures, protein expression tables
ow data was
acquiredCell culture, 2-dimensional gel electrophoresis, MALDI-TOF mass spectrometric
identiﬁcation of proteinsata format Normalized data.
xperimental
factorsCell line identity, treatment with genistein or β-estradiol, 2D/MS proteome
analysisxperimental
featuresM13SV1 human breast epithelial cells and their tumorigenic variants M13SV1-
R2-2 and M13SV1-R2-N1 were treated with different concentrations of genistein
or β-estradiol. Protein extracts were separated by 2-dimensional gel electro-
phoresis. Following identiﬁcation of signiﬁcantly altered protein spots, spots were
picked and identiﬁed using MALDI-TOF mass spectrometry.ata source
locationGerman Federal Institute for Risk Assessment, Berlin, Germanyata accessibility Data is with this article.D
Value of the data
 Differences between M13SV1 human breast epithelial cells and their tumorigenic variants
M13SV1-R2-2 and M13SV1-R2-N1 were identiﬁed by comprehensive proteomic analysis
 Quantitative proteomic responses of the three cell lines to the estrogenic compounds genistein and
β-estradiol were identiﬁed
 Data can help to elucidate biological mechanisms of tumorigenicity and the molecular response of
breast cancer cells to estrogenic substances.1. Data
Proteomic proﬁles of the three cell lines M13SV1 human breast epithelial cells [1] and their tumori-
genic variants M13SV1-R2-2 and M13SV1-R2-N1 [2] were obtained by 2-dimensional gel electrophoresis
followed by identiﬁcation of signiﬁcantly differentially expressed protein spots by MALDI/TOF mass
spectrometry. In addition, the proteomic responses of the three cell lines to treatment with different
concentrations of the estrogenic compounds genistein and β-estradiol were analyzed.
Data are presented in form of an Excel spreadsheet (supplementary ﬁle) containing information about
the identity of the proteins, fold difference in abundance between different cell lines or different treatments,
and corresponding p values. Table 1 of the supplementary ﬁle contains the data of a comparison of cell lines,
i.e. proteins differentially expressed in the tumorigenic cell lines M13SV1-R2-2 (termed “B” throughout the
supplementary ﬁle) and M13SV1-R2-N1 (termed “C”), as compared to the non-tumorigenic line M13SV1
(termed “A”). Tables 2-4 of the supplementary ﬁle contain the data of proteins de-regulated in cell lines A-C
following treatment with genistein (0.1 mM, 1 mM, 10 mM; termed “G1-G3”) or β-estradiol (105 mM,
103 mM, 1 mM; termed “E1-E3”). A legend with explanations is contained in the last tab, termed “expla-
nations”. Please see also Fig. 1 for an overview of cell lines and treatment regimen.2. Experimental design, materials and methods
2.1. Cell culture and treatment
Human breast epithelial cells from line M13SV1 [1] and their tumorigenic derivatives M13SV1-R2-2
and M13SV1-R2-N1 [2] were cultured at 37 °C and 5% CO2 in Michigan-State-University-1 (MSU-1)
medium (Biochrom, Berlin, Germany), supplemented with 5% charcoal-stripped fetal calf serum and
antibiotics (PAA, Pasching, Austria). Cells were treated at 80% conﬂuency with different concentrations
of genistein or β-estradiol for 24 h (see also Fig. 1). Controls were incubated with 0.1% (v/v) EtOH as a
solvent control. For harvesting, cells were washed three times with pre-chilled phosphate-buffered saline
Fig. 1. Overview of cell lines and treatment regimen used in the study. Images show representative photographs of the three cell
lines. For details, please refer to the text. Data contained in this paper comprise a comparative proteomic characterization of the
cell lines (A–C) as well as an analysis of protein deregulation following treatment with the estrogenic substances genistein (G) or
β-estradiol (E). For generation of the cell lines with different tumorigenicity, please refer to published literature [1,2].
A. Braeuning et al. / Data in Brief 8 (2016) 329–333 331and subsequently lysed with lysis buffer (7 M urea, 2 M thiourea, 2% pharmalyte (pH3-10), 0.7% spermine,
1.2% destreak reagent, 4% chaps, serdolit mb-1, and proteinase inhibitor) [3] under shaking for 30 min
following centrifugation at 100,000g for 60 min at 15 °C. Supernatant was stored at 80 °C for further
analysis. Protein content was determined by use of the Bradford assay.2.2. Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis has been described in detail in a previous paper [3]. For details on
the experimental setup, please refer to the latter publication. In brief, isoelectric focusing using IPG strips (pH
3–10) was followed by SDS-PAGE in a 12.5% acrylamide gel. Spots were stained with Tris Ruthenium II. Four
gels (technical replicates) were run per sample, in biological triplicates for each experimental condition.
Protein spots were identiﬁed and quantiﬁed using a VersaDoc imaging system and ProteinMine 1.6.1 software.2.3. Statistical evaluation of gels
Data analysis and statistical evaluation of 2D gels using the software R has been described in detail
in a previous paper [3]. For details on the experimental setup, please refer to the latter publication. A
normalization of 2-DE gel images was performed using the total spot volume, related to an anchor
template gel image as reference. Spot intensity values, given as sum of pixel intensities of each spot
area, were used as a measure for protein spot quantiﬁcation. Only spots quantiﬁed in at least two out
of three biological and two out of four technical replicates were considered for statistical analysis.
Comparison of treatment groups was done using a two-sided Wilcoxon rank sum test and statistical
signiﬁcance was assumed at po0.05). A cutoff of │log2 ratio│Z0.3 for up- or downregulation of
individual protein spots was applied.
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Fig. 2. Overview of the numbers of up- or downregulated protein spots in the cell line comparison experiment. B (left) and C
(middle) indicate the numbers of differentially expressed spots in cell lines B or C, respectively, as compared to cell line A. BþC
(right) indicates the numbers of spots differentially expressed between cell line A and both derivatives, cell lines B and C. For
comparison, data on total spots and the numbers of spots identiﬁed by mass spectrometry are shown.
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Fig. 3. Overview of the numbers of up- or downregulated protein spots in the estrogenic cell treatment experiment. The sum of
spots deregulated in response to cell treatment with different concentrations of β-estradiol (E,) genistein (G), or both (EþG) is
shown separately for the three cell lines. For comparison, data on total spots and the numbers of spots identiﬁed by mass
spectrometry are shown.
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Robot-assisted spot picking and tryptic in-gel digestion methodology has been described in detail in a
previous paper [3]. For details on the experimental setup, please refer to the latter publication. Approxi-
mately 3000 spots were identiﬁed per gel. For an overview of the number of deregulated protein spots in
the cell line comparison and the estrogenic cell treatment experiment, please refer to Fig. 2 and Fig. 3.
2.5. Mass spectrometry
Mass spectrometric analyses were used for protein identiﬁcation, whereas protein quantiﬁcation was
based on spot intensity evaluation of 2D gel electrophoresis (see also section 2.2). Protein identiﬁcation by
mass spectrometry has been described in detail in a previous paper [3]. For details on the experimental
setup, please refer to the latter publication. In brief, digested proteins were manually spotted on an
AnchorChip Target (800/384, Bruker) and matrix solution was added. An Ultraﬂex II mass spectrometer
(Bruker) with smartbeam laser was used for matrix-assisted laser desorption/ionization mass spectro-
metry (MALDI-MS) analysis with a mass range of 500–5000 Da. For more details on mass spectrometer
settings, please refer to [3]. Flex Control and Flex Analysis software (version 3.0, Bruker) were used to
process MS and MS/MS spectra. Protein identiﬁcationwas performed using Biotools software (version 3.2,
Bruker) with Mascot search using the SwissProt database (accessed between January 09th and June 17th,
releases 2015_01 2016_06; taxonomy: homo sapiens). For each protein to identify, two protein spots
were digested and measured independently using peptide mass ﬁngerprinting and MS/MS, giving
4 results. Only proteins identiﬁed with a minimum of 2 hits were considered valid. The column header
“hits” in the Supplementary ﬁle shows the number of identiﬁcations for the two spot measurements.
Sequence coverage of each identiﬁed protein is also indicated in the Supplementary ﬁle.Acknowledgments
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